The company covers an area of 25,000 square meters and currently has nine main buildings: three chemical synthesis workshops, a precision drying and packaging workshop (GMP-compliant), a liquid raw material warehouse, a solid raw material warehouse (divided into raw material storage, intermediate storage, and finished product storage), a power house, a maintenance workshop, an office building, and a dormitory.

All activities involved in production and quality management are conducted in accordance with GMP requirements.

To date, the company has produced three active pharmaceutical ingredients (APIs) that passed domestic GMP inspections in July 2009, July 2011, and July 2015, respectively: Propafenone Hydrochloride, Felodipine, and Amlodipine Besylate. Notably, Amlodipine Besylate received a CEP certificate from the EOQM in August 2011, which was renewed in August 2016. In May 2017, the company passed the EU on-site audit, and in December 2017, it successfully passed the PMDA on-site audit in Japan.